ADC Therapeutics Alternatives & Competitors
12 companies similar to ADC Therapeutics — Innovating Science. Inspiring Hope.
Companies similar to ADC Therapeutics
Pheon Therapeutics
Pheon is an Antibody-Drug Conjugate specialist developing next generation ADCs for a range...
London, United Kingdom
NBE-Therapeutics AG
Next generation antibody drug conjugates
Basel, Switzerland
FatiAbGen Inc.
Best in class multi-modality antibodies for difficult targets in high unmet need diseases...
Korea South
ProfoundBio
An oncology biotherapeutics company
Woodinville, United State...
Track all ADC Therapeutics competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
ImmunoGen
Focusing on core therapeutic areas such as immunology, oncology, neuroscience, eye care, a...
Lisata Therapeutics, Inc.
Targeted Therapy Delivered
United States
Prescient Therapeutics
A clinical stage oncology company developing personalised medicine approaches to cancer; c...
Australia
Alentis Therapeutics
We develop breakthrough treatments for Claudin1-positive tumors and organ fibrosis
Allschwil, Switzerland
Pacylex Pharmaceuticals, Inc.
A new target in cancer care - triggering selective lethality with a new class of drugs.
Edmonton, Canada
DEM Biopharma, Inc.
Novel Target for Solid Tumors
Cambridge, United States
BioInvent International AB
BioInvent is translating cancer antibody biology into innovative immuno-oncology therapies...
Lund, Sweden
Myricx Bio
Developing a new class of ADCs based on NMT inhibition to treat cancer
London, United Kingdom
About ADC Therapeutics
ADC Therapeutics, based in Switzerland, is a commercial-stage global leader in antibody drug conjugates (ADCs), dedicated to transforming cancer treatment. Founded in 2011, the company's expertise spans clinical development to manufacturing. With a focus on pioneering the ADC sector, their approved and marketed product...
Development of Antibody Drug Conjugates, Expansion of Cancer Treatment Products, Clinical Trial Innovation, Medical Affairs and Research
Patients with Hematologic Cancers, Patients with Solid Tumors, Individuals with Relapsed or Refractory Cancer, Healthcare Providers in Oncology
Antibody Drug Conjugates (ADCs), Oncology, Hematological Cancers, Solid Tumors, Clinical-Stage Drug Development, Commercialization, CD19-directed Therapies, ZYNLONTA®, Pyrrolobenzodiazepine (PBD) Technology, Relapsed Or Refractory Diffuse Large B-cell Lymphoma, PSMA-targeting ADC, Cancer Treatment, Pharmaceutical Manufacturing, Drug Discovery, Biotechnology Innovation
B2B, B2D
Product Sales, Licensing
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches ADC Therapeutics and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at ADC Therapeutics on 10 Jun 2026. The 12 companies listed here were last checked between 12 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
